AB
ABUS icon

Amalgamated Bank’s Arbutus Biopharma ABUS Stock Holding History

Amalgamated Bank’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,756
Closed -$23K – 1624
2025
Q4 		$23K Sell
4,756
-286
-6% -$1.29K ﹤0.01% 2042
2025
Q3 		$23K Hold
5,042
– – ﹤0.01% 2052
2025
Q2 		$16K Hold
5,042
– – ﹤0.01% 2192
2025
Q1 		$18K Buy
5,042
+594
+13% +$1.98K ﹤0.01% 2082
2024
Q4 		$15K Hold
4,448
– – ﹤0.01% 2225
2024
Q3 		$17K Hold
4,448
– – ﹤0.01% 2183
2024
Q2 		$14K Buy
4,448
+666
+18% +$2K ﹤0.01% 2259
2024
Q1 		$10K Sell
3,782
-10,899
-74% -$28.2K ﹤0.01% 2419
2023
Q4 		$37K Sell
14,681
-1,126
-7% -$2.21K ﹤0.01% 2369
2023
Q3 		$32K Hold
15,807
– – ﹤0.01% 2438
2023
Q2 		$36K Buy
15,807
+2,060
+15% +$5.36K ﹤0.01% 2449
2023
Q1 		$42K Sell
13,747
-1,938
-12% -$5.47K ﹤0.01% 2364
2022
Q4 		$37K Hold
15,685
– – ﹤0.01% 2548
2022
Q3 		$30K Buy
15,685
+148
+1% +$348 ﹤0.01% 2666
2022
Q2 		$42K Buy
15,537
+5,441
+54% +$13.9K ﹤0.01% 2564
2022
Q1 		$30K Buy
+10,096
New +$30.9K ﹤0.01% 2673

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Amalgamated Bank's ABUS Position: Q1 2026 in Review

Amalgamated Bank sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 4,756 shares — an estimated $23K sold.

Amalgamated Bank first reported a position in ABUS in Q1 2022 and held it in 16 quarters. The position peaked at $42K in Q1 2023. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Amalgamated Bank reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 4,756 Arbutus Biopharma shares in Q1 2026, an estimated $23K.
  • Amalgamated Bank first reported a position in Arbutus Biopharma in Q1 2022 and held it in 16 quarters.
  • Amalgamated Bank's Arbutus Biopharma position peaked at $42K in Q1 2023.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.